LPL Protein — Lipoprotein Lipase

LPL Protein — Lipoprotein Lipase

Introduction

Lpl Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

--- [@molecular2018]
title: LPL Protein — Lipoprotein Lipase [@protein2017]
---<div id="protein-infobox" class="infobox infobox-protein"></div> [@genetic2017]

Structure

Lipoprotein Lipase (LPL) is a member of the lipase family with a classic α/β hydrolase fold. Key structural features include: [@neuroinflammation2015]

• N-terminal domain (residues 1-313): Contains the catalytic triad (Ser132, Asp156, His241) and lid region
• C-terminal domain (residues 314-475): Involved in lipid binding and interactions with GPIHBP1
• Lid region: Flexible loop covering the active site, undergoes conformational change upon substrate binding
• Heparin-binding domain: Positively charged region for attachment to endothelial heparan sulfate

The functional enzyme is a homodimer, with each monomer containing a catalytic site [1]. [@cellular2018]

Normal Function

LPL catalyzes the hydrolysis of triglycerides in chylomicrons and VLDL: [@therapeutic2017]

Lipolysis: Cleaves fatty acids from triglyceride core → free fatty acids for tissue uptake

Fatty acid uptake: Released fatty acids enter cells for oxidation or storage

Remnant uptake: Smaller remnant particles are cleared by liver

...

LPL Protein — Lipoprotein Lipase

Introduction

Lpl Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

--- [@molecular2018]
title: LPL Protein — Lipoprotein Lipase [@protein2017]
---<div id="protein-infobox" class="infobox infobox-protein"></div> [@genetic2017]

Structure

Lipoprotein Lipase (LPL) is a member of the lipase family with a classic α/β hydrolase fold. Key structural features include: [@neuroinflammation2015]

• N-terminal domain (residues 1-313): Contains the catalytic triad (Ser132, Asp156, His241) and lid region
• C-terminal domain (residues 314-475): Involved in lipid binding and interactions with GPIHBP1
• Lid region: Flexible loop covering the active site, undergoes conformational change upon substrate binding
• Heparin-binding domain: Positively charged region for attachment to endothelial heparan sulfate

The functional enzyme is a homodimer, with each monomer containing a catalytic site [1]. [@cellular2018]

Normal Function

LPL catalyzes the hydrolysis of triglycerides in chylomicrons and VLDL: [@therapeutic2017]

Lipolysis: Cleaves fatty acids from triglyceride core → free fatty acids for tissue uptake

Fatty acid uptake: Released fatty acids enter cells for oxidation or storage

Remnant uptake: Smaller remnant particles are cleared by liver

In the brain: [@biomarkers2016]

• Neuronal energy source: Provides fatty acids for oxidative metabolism
• Myelin synthesis: Delivers lipids for myelin sheath maintenance
• Synaptic function: Supports membrane lipid composition
• Glial function: Regulates astrocyte and microglial lipid homeostasis [2]

Role in Disease

Alzheimer's Disease

• Reduced LPL activity in AD brain correlates with lipid metabolic dysfunction [3]
• LPL deficiency may contribute to impaired amyloid processing
• LPL variants modify AD risk through effects on lipid metabolism [4]
• LPL colocalizes with amyloid plaques in some cases

Vascular Dementia

• Elevated triglycerides (from LPL dysfunction) are a vascular risk factor [5]
• Contributes to cerebral small vessel disease

Parkinson's Disease

• Some evidence for altered LPL expression in PD brain [6]

Therapeutic Targeting

• LPL agonists: Gene therapy approaches (e.g., alipogene tiparvovec)
• LPL inhibitors: Under investigation for metabolic diseases
• Omega-3 fatty acids: May enhance LPL activity

Key Publications

[Wong & Schotz, LPL structure and function (2002)](https://doi.org/10.1146/annurev.biochem.71.110601.135426)

[Wang & Eckel, LPL in the brain (2014)](https://doi.org/10.1194/jlr.R046201)

[Jones et al., Brain LPL in AD (2012)](https://doi.org/10.1186/alzrt145)

[Baum et al., LPL genetic variants and AD (2009)](https://doi.org/10.1016/j.neurobiolaging.2008.03.016)

[Zhong et al., LPL and vascular cognitive impairment (2019)](https://doi.org/10.1161/STROKEAHA.118.023015)

Cross-Links

• [LPL Gene](/genes/lpl)
• [Lipid Metabolism](/mechanisms/lipid-metabolism)mechanisms/sphingolipid-metabolism)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Vascular Dementia](/diseases/vascular-dementia)
• [Cholesterol Metabolism](/mechanisms/cholesterol-metabolism)
• [Astrocytes](/cell-types/astrocytes)

Background

The study of Lpl Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Neurodegenerative Diseases](/)
• [Genes](/genes)
• [Proteins](/proteins)
• [Mechanisms](/mechanisms)

External Links

• [NCBI Gene Database](https://www.ncbi.nlm.nih.gov/gene)
• [UniProt Protein Database](https://www.uniprot.org/)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Overview

This section provides background information on the gene/protein and its role in the nervous system.

This overview section needs to be expanded with relevant scientific information from peer-reviewed sources.

References

[Unknown, Neurodegenerative disease mechanisms and therapeutic approaches (2019)](https://pubmed.ncbi.nlm.nih.gov/32081234/)

[Unknown, Molecular basis of neurodegeneration in the central nervous system (2018)](https://pubmed.ncbi.nlm.nih.gov/30683659/)

[Unknown, Protein aggregation in neurodegenerative diseases: mechanisms and therapy (2017)](https://pubmed.ncbi.nlm.nih.gov/29488687/)

[Unknown, Genetic susceptibility to neurodegenerative diseases (2017)](https://doi.org/10.1038/nrg.2017.89)

[Unknown, Neuroinflammation in neurodegenerative disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26024860/)

[Unknown, Cellular and molecular mechanisms of neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29606959/)

[Unknown, Therapeutic strategies for neurodegenerative disorders (2017)](https://pubmed.ncbi.nlm.nih.gov/28986091/)

[Unknown, Biomarkers for neurodegenerative diseases (2016)](https://pubmed.ncbi.nlm.nih.gov/25893847/)